

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue:

Laxmi Dental Limited

- | | |
|---|--|
| 1. Type of Issue (IPO/FPO) | IPO |
| 2. Issue Size (Rs. Cr) | INR 698.06 Cr |
| 3. Grade of issue along with name of the rating agency | |
| Name | NA |
| Grade | NA |
| 4. Subscription Level (Number of times) | 114.67 times (excluding the Anchor Investor Portion) as per the bid books of NSE and BSE after removing multiple and duplicate bids. |

Source: Minutes of the Meeting held for the finalization of the Basis of Allotment dated January 16, 2025

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	44.67 %
(ii) at the end of the 1st Quarter immediately after the listing of the issue [^]	NA
(iii) at the end of 1st FY (March 31, 2025) [^]	NA
(iv) at the end of 2nd FY (March 31, 2026) [^]	NA
(v) at the end of 3rd FY (March 31, 2027) [^]	NA

(*) As per the shareholding pattern as on the date of listing.

([^]) QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed.

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated

(Rs in Crores)

Parameters	1st FY (March 31, 2025)*	2nd FY (March 31, 2026)*	3rd FY (March 31, 2027)*
Income from operations	N.A.	N.A.	N.A.
Net Profit for the period	N.A.	N.A.	N.A.
Paid-up equity share capital	N.A.	N.A.	N.A.
Reserves excluding revaluation reserves	N.A.	N.A.	N.A.

* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on the BSE Limited and the National Stock Exchange of India Limited .

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)*	N.A.
(ii) at the end of 2nd FY (March 31, 2026)*	N.A.
(iii) at the end of 3rd FY (March 31, 2027)*	N.A.

* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed/ Resigned
(i) at the end of 1st FY (March 31, 2025)*	N.A.	N.A.
(ii) at the end of 2nd FY (March 31, 2026)*	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2027)*	N.A.	N.A.

For FY 2024-25 there has been no change in Directors till February 15, 2025.

*Changes in directors not disclosed as reporting for relevant fiscal years has not been completed

9. Status of implementation of project/ commencement of commercial production

- (i) **As disclosed in the offer document:** Not Applicable
- (ii) **Actual implementation:** Not Applicable
- (iii) **Reasons for delay in implementation, if any:** Not Applicable.

10. Status of utilization of issue proceeds

- (i) **As disclosed in the offer document :**

The Company propose to deploy the Net Proceeds towards the Objects in accordance with the estimated schedule of implementation and deployment of funds, as set forth in the table below:

(in ₹ million)

Sr. No.	Particulars	Total estimated amount/ expenditure	Amount to be funded from the Net Proceeds	Estimated deployment of the Net Proceeds	
				Fiscal 2025	Fiscal 2026
1	Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the Company	229.84	229.84	229.84	NA
2	Investment in certain Subsidiaries the repayment/prepayment, in full or in part, of certain outstanding borrowings	46.00	46.00	46.00	NA

3	Funding the capital expenditure requirements for purchase of new machinery for the Company	435.07	435.07	202.14	232.92
4	Investment in the Subsidiary, Bizdent Devices Private Limited, for the capital expenditure requirements for the purchase of new machinery	250.04	250.04	100.19	149.85
5	General Corporate Purpose	320.75	320.75	250.00	70.75
Total		1281.70	1281.70	828.17	453.52

(ii) **Actual utilization:** Will be updated in due course.

(iii) **Reasons for deviation, if any:** Will be updated in due course.

11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	Will be updated in due course.
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12. Pricing Data

Issue Price (Rs.): 428/-

Designated Stock Exchange: BSE Limited

Listing Date: January 20, 2025

Price parameters	At close of listing day (i.e. January 20, 2025)	At close of 30th calendar day from listing day*	At close of 90th calendar day from listing day*	As at the end of 1st FY after the listing of the issue (May 31, 2025)*		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	550.65	NA	NA	NA	NA	NA
BSE Sensex	77,073.44	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2026)*			As at the end of 3rd FY after the listing of the issue (March 31, 2027)*		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	NA	NA	NA	NA	NA	NA
BSE Sensex	NA	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: BSE website

* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed

13. **Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)**

Accounting Ratio		As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2025) ⁽²⁾	At the end of 2nd FY (March 31, 2026) ⁽²⁾	At the end of 3rd FY (March 31, 2027) ⁽²⁾
EPS	Issuer:	--	--	--	--
	Consolidated (Basic)	4.80	N.A	N.A	N.A
	Consolidated (Diluted)	4.80	N.A	N.A	N.A
	Peer Group :	--	--	--	--
	Poly Medicare Limited	Basic – 26.92 Diluted – 26.90	N.A	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A
P/E	Issuer:	--	--	--	--
	Consolidated	83.76	N.A	N.A	N.A
	Peer Group	--	--	--	--

	Poly Medicure Limited	94.02	N.A	N.A	N.A
	Industry Composite:	94.02	N.A	N.A	N.A
RoNW (%)	Issuer:	--	--	--	--
	Consolidated	78.78	N.A	N.A	N.A
	Peer Group	--	--	--	--
	Poly Medicure Limited	19.05	N.A	N.A	N.A
	Industry Composite:	NA	N.A	N.A	N.A
NAV	Issuer:	--	--	--	--
	Consolidated	8.63	N.A	N.A	N.A
	Peer Group	--	--	--	--
	Poly Medicure Limited	153.22	N.A	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A

Notes:

- (1) Prospectus dated January 16, 2025.
- (2) Not disclosed as the reporting for the relevant fiscal years has not been completed.

14. Any other material information

Particulars	Date
The Company has informed about the change of name of Registrar and Share Transfer Agent from Link Intime India Private Limited to MUFG Intime India Private Limited with effect from 31st December, 2024.	29-January-2025
The Company has informed about the board approval for the following : <ol style="list-style-type: none"> 1) To grant in- principal approval for providing an unsecured loan to Signature Smiles Dental Clinic Pvt. Ltd, a subsidiary of the Company up to Rs. 2,00,00,000/- (Rupees Two Crores Only) in one or more tranches. 2) To grant in- principal approval in- principal approval for investment in Bizdent Devices Private Limited, a wholly owned Subsidiary of the Company up to Rs. 20,00,00,000/- (Twenty Crores Only) in one or more traches. 	13-February-2025

The Company further informed that company will update further at the time of execution of definitive agreements for the above-mentioned transactions.	
---	--

Source- Stock Exchange Filings

All the above information has been updated till February 20,2025, unless indicated otherwise.

NUVAMA